Leading experts to discuss advances in
technologies to prevent esophageal cancer through esophageal
precancer screening
NEW
YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company") a commercial-stage, cancer prevention medical
diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
announced that it will be participating as the sole Diamond Sponsor
at the 20th International Society for Diseases of the
Esophagus (ISDE) World Congress being held from September 22-24, 2024, at the Edinburgh
International Convention Centre in Edinburgh, Scotland. Lucid will be
highlighting the unprecedented performance of its
EsoGuard® Esophageal DNA Test for early detection
of esophageal precancer to conference participants.
Lucid will also host a symposium entitled Non-Endoscopic
Screening for Barrett's Esophagus chaired by distinguished
experts in esophageal diseases, including Vani Konda, M.D., Medical Director of the Center
for Esophageal Diseases at Baylor Scott & White Health, and
Nicholas Shaheen, M.D., M.P.H.,
Professor and Chief of Gastroenterology & Hepatology at
UNC Chapel Hill, the current ISDE
President and lead author of the American College of
Gastroenterology (ACG) guidelines on esophageal precancer
screening. The symposium's panel discussion will include
Vivek Kaul, M.D., Professor in the
Division of Gastroenterology & Hepatology at the
University of Rochester Medical Center,
and Rehan Haidry, M.D., Consultant
Gastroenterologist at Cleveland Clinic London.
"At Lucid, we are committed to be the leading international
voice on esophageal cancer prevention though early detection of
esophageal precancer and are excited to have a strong presence at
this year's ISDE World Congress, a premier global event for
international experts in esophageal disease," said Lishan Aklog, M.D., Lucid's Chairman and Chief
Executive Officer. "We are particularly excited to host our
first international symposium on non-endoscopic esophageal
precancer screening led by renowned specialists from the United States and Great Britain. We are grateful to our
longstanding collaborator, Dr. Shaheen and his esteemed colleagues
Dr. Konda, Dr. Kaul, and Dr. Haidry for their invaluable
contributions to the field and for leading what we believe will be
an outstanding symposium."
The ISDE World Congress is a premier global conference that
brings together experts from various specialties involved in the
clinical management and research of esophageal diseases. The event
provides a valuable platform for collaboration and knowledge
exchange among leading experts in esophageal diseases. This year's
congress will cover a wide range of topics, including diagnostics,
novel therapies, and the latest advancements impacting the field of
esophageal diseases.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention
medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:
PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test, performed
on samples collected in a brief, noninvasive office procedure with
its EsoCheck® Esophageal Cell Collection Device,
represent the first and only commercially available tools designed
with the goal of preventing cancer and cancer deaths through
widespread, early detection of esophageal precancer in at-risk
patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-host-symposium-on-non-endoscopic-esophageal-precancer-screening-at-the-20th-international-society-for-diseases-of-the-esophagus-isde-world-congress-302243469.html
SOURCE Lucid Diagnostics